Alzheimer Therapy and diagnostic with approved medical device software

Transforming Alzheimer's Therapy with approved medical device software wit

Introduction:
My client, a pioneering medical device software company that is poised to revolutionise the treatment of Alzheimer's dementia. As a spin-off of JOANNEUM RESEARCH in Graz/Austria and in close collaboration with the renowned Medical University Graz – Dept. of Neurology, my client is on the cusp of becoming the first-ever approved therapy for this debilitating disease.

1. Breakthrough Alzheimer's Therapy:
My client is on the forefront of medical innovation, developing an approved medical device software specifically designed for Alzheimer's therapy. Our product, BRAINMEE, offers a ground breaking solution to address the unmet medical needs of Alzheimer's patients worldwide, opening up new possibilities for effective treatment.

2. Research collaboration with esteemed institution:
Through a strategic research collaboration with the esteemed Medical University Graz – Dept. of Neurology, has gained invaluable insights and expertise. This partnership ensures that our product development remains at the cutting edge of scientific advancements, giving us a distinct advantage in developing effective therapies for Alzheimer's dementia.

3. Market traction and validation:
My client is already in use by paying customers, showcasing its market viability and functionality. Although its current application is not as a medical device, this early market traction validates its potential. With the investment, my client can accelerate the medical device approval process, unlocking the full therapeutic potential in the treatment of Alzheimer's.

4. Promising Path to Approval:
My client is intensively preparing for the medical device approval process, and the prospects for success are highly favourable. All stakeholders involved share an unwavering belief in the potential of our solution. Upon approval, the application and marketing opportunities for Alzheimer's therapy will be exceedingly positive, offering an exceptional value proposition for investors.

5. Future Growth Potential:
In addition to Alzheimer's therapy, my client has strategic plans to expand into diagnostics, broadening our scope within the neurology space. By investing in, one not only participate in the ground breaking Alzheimer's therapy market but also position yourself for future growth opportunities as my client develops innovative diagnostic solutions.

My client is the trailblazers of Alzheimer's therapy with approved medical device software. The investment of approx. 5 million euro, a catalyst for transformation in the treatment of Alzheimer's dementia, impacting the lives of millions worldwide.